Table 3. Results of prevalence study of anti-TOSV immunoglobulin G, Granada*.
| Area | <15 y, no. (pos) | 15–40 y, no. (pos) | 41–65 y, no. (pos) | >65 y, no. (pos) | No. | Pos (%) |
|---|---|---|---|---|---|---|
| Urban | 52 (2) | 141 (22) | 60 (20) | 34 (15) | 287 | 59 (20.6) |
| Metropolitan | 51 (7) | 127 (24) | 62 (18) | 42 (28) | 282 | 77 (27.3) |
| South | 34 (3) | 76 (14) | 54 (12) | 28 (19) | 192 | 48 (25.0) |
| West/southwest | 3 (0) | 40 (7) | 20 (10) | 9 (6) | 72 | 23 (31.9) |
| North/northeast | 19 (3) | 71 (15) | 35 (6) | 21 (13) | 146 | 37 (25.3) |
| Total | 159 (15, 9.4%) | 455 (82, 18%) | 231 (66, 28.6%) | 134 (81, 60.4%) | 979 | 244 (24.9) |
*TOSV, Toscana virus; pos, positives.